Group 1 - The company expects a revenue growth of approximately 110% to 120% for the fiscal year ending December 31, 2025, compared to the fiscal year ending December 31, 2024, primarily due to significant progress in the commercialization of its core product, the TUMAI® laparoscopic surgical robot [1] - The company has signed over 100 new orders in overseas markets, with overseas sales revenue exceeding five times that of the previous year, indicating strong global expansion momentum [1] - As of the date of the announcement, the total commercial orders for TUMAI globally exceeded 180 units, with the cumulative installed base surpassing 120 units [1] Group 2 - The company anticipates an adjusted net loss of no more than RMB 240 million for the fiscal year ending December 31, 2025, which represents a reduction of over 50% compared to the adjusted net loss of approximately RMB 482 million for the fiscal year ending December 31, 2024 [1] - The reduction in loss is attributed to rapid revenue growth and significant decreases in product costs and operating expenses due to various cost control measures [1] - The company expects a substantial narrowing of free cash flow net outflow by over 80% for the fiscal year ending December 31, 2025, to no more than RMB 70 million [2]